Reports
Sale
Global Granulomatosis with Polyangiitis Treatment Market Share, Size, Research: By Drug Class: Steroids, Immunosuppressant, Others; By Route of Administration: Oral, Intravenous, Others; By Distribution Channels: Hospital Pharmacies, Others; Regional Analysis; Competitive Landscape: Industry Events and Developments; 2024-2032
Global Granulomatosis with Polyangiitis Treatment Market Outlook
The global granulomatosis with polyangiitis treatment market size is expected to grow in the forecast period of 2024-2032 at a CAGR of 4.90%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Usage of Immunosuppressants to Augment the Global Granulomatosis with Polyangiitis Treatment Industry
Immunosuppressants for the treatment of granulomatosis with polyangiitis are gaining traction in the healthcare industry owing to the high response rate of this medication. Immunosuppressants such as cyclophosphamide with prednisone are widely used in the treatment of this disease as they pose less chance of fatality during the treatment.
Such immunosuppressants are consumed orally which is a major advantage of this medication amidst the changing patient preference towards minimally invasive treatment procedures. Methotrexate and azathioprine are some other examples of immunosuppressants which calm down the immune system of body, thereby, keeping the disease under control. Therefore, the anticipated increase in the demand for immunosuppressants are likely to aid the segment’s growth in the coming years.
North America Leads the Market for Granulomatosis with Polyangiitis Treatment
Countries such as the United States are high healthcare spenders globally. The regulations of the government encouraging the development of therapeutics and diffusing knowledge about this disorder are propelling the market growth. In addition to this, the growing FDA-approvals of immunosuppressants and drugs are further expanding the opportunities for the global granulomatosis with polyangiitis treatment market.
Market Segmentation
Granulomatosis with polyangiitis is defined as a medical condition which causes inflammation of blood vessels. Body parts of humans affected by this disease include ears, nose, and kidney, among others. This disease is prevalent among children, adults and geriatrics, and granulomatosis with polyangiitis treatment is aimed at diagnosis and various medications.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market can be segmented into:
- Steroids
- Immunosuppressant
- Others
By route of administration, the market has been divided into:
- Oral
- Intravenous
- Others
On the basis of distribution channel, the granulomatosis with polyangiitis treatment market has been categorised into:
- Hospital Pharmacies
- Retail Pharmacies
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Escalating Prevalence to Boost the Growth of the Granulomatosis with Polyangiitis Treatment Industry
The escalating prevalence of granulomatosis with polyangiitis owing to the increasing cases of immunological disorders caused by the sedentary lifestyles led by the working class population is driving the global granulomatosis with polyangiitis treatment market. This disease causes severe symptoms such as chest pain, tiredness, nosebleed, loss of appetite, and weight-loss, among others, which compel the victims to go for check-ups. This factor is further invigorating the market growth.
Over the forecast period, the anticipated increase in the research and development activities by major biopharmaceutical companies aimed towards developing effective therapeutics to counter this disorder are likely to lead to improved medications. Moreover, the market is anticipated to be aided by organised X-rays, CT scans, and MRI in modern hospitals which is bolstering the diagnosis process for timely treatment of this condition. Furthermore, the market is likely to be navigated by the increasing geriatric population, coupled with the favourable reimbursement policies of the government.
Key Players in the Global Market for Granulomatosis with Polyangiitis Treatment
The report gives a detailed analysis of the following key players in the global granulomatosis with polyangiitis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Genentech, Inc.
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Region
7 Opportunities and Challenges in the Market
8 Global Granulomatosis with Polyangiitis Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Granulomatosis with Polyangiitis Treatment Historical Market (2018-2023)
8.3 Global Granulomatosis with Polyangiitis Treatment Market Forecast (2024-2032)
8.4 Global Granulomatosis with Polyangiitis Treatment Market by Drug Class
8.4.1 Steroids
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Immunosuppressant
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Others
8.5 Global Granulomatosis with Polyangiitis Treatment Market by Route of Administration
8.5.1 Oral
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Intravenous
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Others
8.6 Global Granulomatosis with Polyangiitis Treatment Market by Distribution Channels
8.6.1 Hospital Pharmacies
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Retail Pharmacies
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Others
8.7 Global Granulomatosis with Polyangiitis Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Granulomatosis with Polyangiitis Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Granulomatosis with Polyangiitis Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Granulomatosis with Polyangiitis Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Granulomatosis with Polyangiitis Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Granulomatosis with Polyangiitis Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Genentech, Inc.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 GlaxoSmithKline plc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Teva Pharmaceutical Industries Ltd.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Pfizer Inc.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Granulomatosis with Polyangiitis Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Drug Class (USD Million), 2018-2023
3. Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4. Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
5. Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
6. Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
7. Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
8. Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Granulomatosis with Polyangiitis Treatment Market Structure.
Key Questions Answered in the Report
The market is estimated to grow at a CAGR of 4.90% between 2024 and 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The growing rapid advancements in healthcare infrastructure is likely to be a key trend in the market.
The major drivers of the market include the increasing cases of immunological disorders, severe symptoms of the disease, and improvements in medications.
Steroids, and immunosuppressants, among others are the different segments based on drug class.
Oral, and intravenous, among others are the different segments based on route of administration.
Hospital pharmacies, and retail pharmacies, among others are the different distribution channels included in the market report.
The major players in the industry are Genentech, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3199
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4199
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5199
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER